期刊
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
卷 17, 期 9, 页码 533-542出版社
NATURE PORTFOLIO
DOI: 10.1038/s41575-020-0332-6
关键词
-
资金
- PROLIFICA programme
- European Commission
- MRC UK
- Gilead Sciences
- Abbott
- Echosens
- Cepheid
- Spanish Ministry of Science, Innovation and Universities Miguel Servet grant (Instituto de Salud Carlos III/ESF, European Union) [CP18/00074]
- Spanish Ministry of Science, Innovation and Universities through the Centro de Excelencia Severo Ochoa 2019-2023 Programme [CEX2018-000806-S]
- Government of Catalonia through the CERCA Programme
- International Coalition to eliminate HBV
- ANRS
- MRC [MR/R011117/1] Funding Source: UKRI
The global burden of viral hepatitis is substantial; in terms of mortality, hepatitis B virus and hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top four global infectious diseases. In 2016, the 194 Member States of the World Health Organization committed to eliminating viral hepatitis as a public health threat by 2030, with a particular focus on hepatitis B virus and hepatitis C virus infection. With only 10 years to go until the 2030 deadline is reached, and although much progress has been made towards elimination, there are still some important gaps in terms of policy and progress. In this Viewpoint, we asked a selection of scientists and clinicians working in the viral hepatitis field for their opinions on whether elimination of viral hepatitis by 2030 is feasible, what the key areas of progress are and what the focus for the next 10 years and beyond should be for viral hepatitis elimination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据